Literature DB >> 34114192

Pituitary adenoma…nomen omen?

Andrea Giustina1.   

Abstract

BACKGROUND: In 2017, the International Pituitary Pathology Club proposed to rename pituitary adenoma as pituitary neuroendocrine tumors (PitNETs) but since no consensus on this new terminology was obtained the Pituitary Society decided to host on this topic an international multidisciplinary virtual workshop, Pituitary Neoplasm Nomenclature (PANOMEN), to which several Societies participated with the designation of their representatives in the expert panel. Main conclusion of the meeting was that there was not yet a case for adopting the PitNET nomenclature and main recommendation was that the term adenoma is retained. AIM: Aim of this Editorial is to comment the outcome of the recently published document of the meeting.
CONCLUSIONS: Ideally, only the combination of pathological, neuroradiological, and clinical data can define the degree of agressiveness/invasion of a pituitary adenoma and effectively guide treament. This may be classically obtained only with a close multisciplinary collaboration into a PTCOE. It is proposed that improved definition of "invasive" and "aggressive" neoplasms may represent the most clinically effective development in the clinico-neuroradiological-pathological denomination and classification of pituitary adenomas.

Entities:  

Keywords:  Acromegaly; Cushing disease; Neuroendocrine tumor; Pituitary adenoma; Pituitary pathology; Prolactinoma

Year:  2021        PMID: 34114192     DOI: 10.1007/s12020-021-02785-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  18 in total

Review 1.  The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective.

Authors:  Pietro Mortini; Gianluca Nocera; Francesca Roncelli; Marco Losa; Anna Maria Formenti; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

2.  A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.

Authors:  Andrea Giustina; Ariel Barkan; Albert Beckers; Nienke Biermasz; Beverly M K Biller; Cesar Boguszewski; Marek Bolanowski; Vivien Bonert; Marcello D Bronstein; Felipe F Casanueva; David Clemmons; Annamaria Colao; Diego Ferone; Maria Fleseriu; Stefano Frara; Monica R Gadelha; Ezio Ghigo; Mark Gurnell; Anthony P Heaney; Ken Ho; Adriana Ioachimescu; Laurence Katznelson; Fahrettin Kelestimur; John Kopchick; Michal Krsek; Steven Lamberts; Marco Losa; Anton Luger; Pietro Maffei; Monica Marazuela; Gherardo Mazziotti; Moises Mercado; Pietro Mortini; Sebastian Neggers; Alberto M Pereira; Stephan Petersenn; Manel Puig-Domingo; Roberto Salvatori; Ilan Shimon; Christian Strasburger; Stylianos Tsagarakis; A J van der Lely; John Wass; Maria Chiara Zatelli; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

3.  Current management practices for acromegaly: an international survey.

Authors:  A Giustina; M D Bronstein; F F Casanueva; P Chanson; E Ghigo; K K Y Ho; A Klibanski; S Lamberts; P Trainer; S Melmed
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

Review 4.  Pituitary Tumors Centers of Excellence.

Authors:  Stefano Frara; Gemma Rodriguez-Carnero; Ana M Formenti; Miguel A Martinez-Olmos; Andrea Giustina; Felipe F Casanueva
Journal:  Endocrinol Metab Clin North Am       Date:  2020-07-15       Impact factor: 4.741

Review 5.  Multidisciplinary management of acromegaly: A consensus.

Authors:  Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed
Journal:  Rev Endocr Metab Disord       Date:  2020-09-10       Impact factor: 6.514

Review 6.  Hyperprolactinemia and prolactinomas.

Authors:  Tatiana Mancini; Felipe F Casanueva; Andrea Giustina
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

7.  Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.

Authors:  Antonio Bianchi; Andrea Giustina; Vincenzo Cimino; Roberto Pola; Flavia Angelini; Alfredo Pontecorvi; Laura De Marinis
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

8.  Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study.

Authors:  Andrea Giustina; Marcello D Bronstein; Philippe Chanson; Stephan Petersenn; Felipe F Casanueva; Caroline Sert; Aude Houchard; Shlomo Melmed
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 9.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

10.  Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Authors:  Ken Ho; Maria Fleseriu; Ursula Kaiser; Roberto Salvatori; Thierry Brue; M Beatriz Lopes; Pamela Kunz; Mark Molitch; Sally A Camper; Mônica Gadelha; Luis V Syro; Edward Laws; Martin Reincke; Hiroshi Nishioka; Ashley Grossman; Ariel Barkan; Felipe Casanueva; John Wass; Adam Mamelak; Laurence Katznelson; Aart J van der Lely; Sally Radovick; Martin Bidlingmaier; Margaret Boguszewski; Jens Bollerslev; Andrew R Hoffman; Nelson Oyesiku; Gerald Raverot; Anat Ben-Shlomo; Rob Fowkes; Ilan Shimon; Hidenori Fukuoka; Alberto M Pereira; Yona Greenman; Anthony P Heaney; Mark Gurnell; Gudmundur Johannsson; Robert Y Osamura; Michael Buchfelder; Maria Chiara Zatelli; Marta Korbonits; Philippe Chanson; Nienke Biermasz; David R Clemmons; Niki Karavitaki; Marcello D Bronstein; Peter Trainer; Shlomo Melmed
Journal:  J Endocr Soc       Date:  2021-02-09
View more
  2 in total

1.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

Review 2.  Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area.

Authors:  Giovanni Tulipano
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.